Yongting Wang
Head of Biology, Cell & Gene Therapy Research Astellas Pharma
Seminars
Wednesday 9th September 2026
Advancing iPSC-Derived Ocular Cell Therapies to Improve Vision Restoration & Support Progression into Pivotal Trials
3:40 pm
- Reviewing pipelines with iPSC-derived retinal cell replacement, focusing on preclinical engraftment, structural preservation, and early clinical functional readouts
- Defining meaningful visual endpoints, durability markers and safety criteria that demonstrate clinical benefit and support the move from early-phase studies toward larger efficacy trials
